港股异动丨微创医疗(0853.HK)高开逾5% 附属增资引入珠海高瓴等投资者
格隆汇9月1日丨微创医疗(0853.HK)高开逾5%,报37.1港元,总市值669.5亿港元。微创医疗发布公告,2020年8月31日,该附属公司(公司全资附属上海默化人工智能科技有限公司)及目标公司与该等投资者及上海常隆订立协议,据此,该附属公司同意向该等投资者转让目标公司7.1429%注册资本以获取人民币15亿元;目标公司的现有股东上海常隆同意向该等投资者转让目标公司2.3809%的注册资本,以获取人民币5亿元;及该等投资者同意向目标公司注入额外资本合共人民币15亿元。该等投资者包括珠海高瓴崇恒股权投资合伙企业(有限合伙)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.